Homology Medicines, Inc.

NASDAQ:FIXX

0.9347 (USD) • At close March 25, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q1
Revenue 01.41800.3540.8020.8020.8020.8020.8020.8021.6772.18729.3050.980.5670.5670.5880.5630.4410.3920.270.980.9540.9260.8230000
Cost of Revenue 01.2870.1360.5640.5870.6330.6350.786000000000000000000000
Gross Profit 00.131-0.136-0.210.2150.1690.1670.0160.8020.8021.6772.18729.3050.980.5670.5670.5880.5630.4410.3920.270.980.9540.9260.8230000
Gross Profit Ratio 00.0920-0.5930.2680.2110.2080.02111111111111111110000
Reseach & Development Expenses 9.8411.51317.51922.98219.98827.14925.85421.07524.27323.64623.98723.69721.75523.19520.41727.47129.3120.34225.69122.82720.53616.28113.39410.297.9989.5764.9474.0562.799
General & Administrative Expenses 5.0027.9016.8428.1888.3258.1477.818.03414.14710.7818.3519.0428.6617.5878.4238.7937.775.786.0385.5384.8575.0873.8434.5273.8282.6861.7181.9821.892
Selling & Marketing Expenses 00000000000000000000000000000
SG&A 5.0027.9016.8428.1888.3258.1477.818.03414.14710.7818.3519.0428.6617.5878.4238.7937.775.786.0385.5384.8575.0873.8434.5273.8282.6861.7181.9821.892
Other Expenses 02.6876.640000000000000000000000000-0.876
Operating Expenses 14.8439.41431.00131.1728.31335.29633.66429.10938.4234.42732.33832.73930.41630.78228.8436.26437.0826.12231.72928.36525.39321.36717.23714.81711.82612.2636.6656.0394.692
Operating Income -14.843-9.414-31.001-30.816-27.511-34.494-32.862-28.307-37.618-33.625-30.661-30.552-1.111-29.802-28.273-35.697-36.492-25.559-31.288-27.973-25.123-20.387-16.283-13.891-11.002-12.263-6.665-6.039-4.692
Operating Income Ratio 0-6.6390-87.051-34.303-43.01-40.975-35.296-46.905-41.926-18.283-13.97-0.038-30.41-49.864-62.958-62.061-45.398-70.948-71.36-93.048-20.803-17.065-14.993-13.3620000
Total Other Income Expenses Net 16.0487.2591.4231.5111.4691.4551.2690.474131.2810.0420.0530.0520.0380.0110.0410.3571.1611.3921.6611.7031.2711.3861.4870.9960.4790.3570.1370.036-0.876
Income Before Tax 1.205-2.155-29.578-29.305-26.042-33.039-31.593-27.83393.663-33.583-30.608-30.5-1.073-29.791-28.232-35.34-35.331-24.167-29.627-26.27-23.852-19.001-14.796-12.894-10.523-11.906-6.528-6.003-5.555
Income Before Tax Ratio 0-1.520-82.782-32.471-41.196-39.393-34.704116.787-41.874-18.252-13.946-0.037-30.399-49.792-62.328-60.087-42.925-67.181-67.015-88.341-19.389-15.507-13.917-12.780000
Income Tax Expense 0.17613.9643.3765.7392.802-0.101-0.046-0.1050.9670000000000000000000-0.013
Net Income 1.029-16.119-32.954-35.044-28.844-32.938-31.547-27.72892.105-33.583-30.608-30.5-1.073-29.791-28.232-35.34-35.331-24.167-29.627-26.27-23.852-19.001-14.796-12.894-10.523-11.906-6.528-6.003-5.555
Net Income Ratio 0-11.3670-98.994-35.965-41.07-39.335-34.574114.844-41.874-18.252-13.946-0.037-30.399-49.792-62.328-60.087-42.925-67.181-67.015-88.341-19.389-15.507-13.917-12.780000
EPS 1.03-50.01-102.53-109.14-89.96-103.14-99.34-87.51.61-106.01-97.2-97.2-3.83-118.57-112.36-140.71-140.85-98.95-121.46-109.77-114.84-93.3-71.45-62.97-42.09-115.2-63.16-58.08-53.75
EPS Diluted 0.44-50.01-102.53-109.14-89.96-103.14-98.85-86.971.59-105.85-96.48-97.17-3.83-118.57-112.36-140.71-140.85-96.34-121.46-109.77-114.84-91.49-71.45-62.97-42.09-115.2-63.16-58.08-53.75
EBITDA -14.843-9.414-31.001-30.599-27.286-34.198-32.541-27.979-168.519-31.552-28.562-28.4510.969-27.746-26.263-33.926-34.364-23.84-29.597-26.331-23.857-19.824-16.015-13.654-10.782-12.062-6.475-5.875-4.561
EBITDA Ratio 0-6.6390-86.438-34.022-42.641-40.575-34.887-210.123-39.342-17.032-13.0090.033-28.312-46.319-59.834-58.442-42.345-67.113-67.171-88.359-20.229-16.785-14.737-13.0950000